Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Curr Med Chem Anticancer Agents. 2002 Sep;2(5):613-26.

How to inhibit telomerase activity for cancer therapy.

Author information

  • 1Department of Obstetrics and Gynecology, Kanazawa University, School of Medicine, 13-1, Takaramachi, Kanazawa, Ishikawa 920-8641, Japan. satoruky@med.kanazawa-u.ac.jp


Telomerase is a target for anticancer research because telomerase activity is closely correlated with malignancy. Inhibition of telomerase activity should increase telomere shortening, which destabilizes chromosomes, thus leading to cellular senescence and death. Extensive investigations have addressed the molecular mechanisms of telomerase activation in cancers. Based on results from these studies, various attempts have been made to inhibit telomerase activity using molecular techniques in cancer cells. Antisense oligonucleotides directed to human telomerase RNA, the dominant negative form of human telomerase reverse transcriptase (hTERT), hammerhead ribozymes that cut hTR and agents that interact with quadruplex DNA represent potential telomerase inhibitors. This review includes a summary of recent attempts to inhibit telomerase activity in cancer cells and a discussion of how these tools can be applied to cancer therapy, especially in combination with established anti-cancer agents.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk